» Articles » PMID: 36385416

Updated Immunomodulatory Roles of Gut Flora and MicroRNAs in Inflammatory Bowel Diseases

Overview
Journal Clin Exp Med
Specialty General Medicine
Date 2022 Nov 17
PMID 36385416
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory bowel disease is a heterogeneous intestinal inflammatory disorder, including ulcerative colitis (UC) and Crohn's disease (CD). Existing studies have shown that the pathogenesis of IBD is closely related to the host's genetic susceptibility, intestinal flora disturbance and mucosal immune abnormalities, etc. It is generally believed that there are complicated interactions between host immunity and intestinal microflora/microRNAs during the occurrence and progression of IBD. Intestinal flora is mainly composed of bacteria, fungi, viruses and helminths. These commensals are highly implicated in the maintenance of intestinal microenvironment homeostasis alone or in combination. MiRNA is an endogenous non-coding small RNA with a length of 20 to 22 nucleotides, which can perform a variety of biological functions by silencing or activating target genes through complementary pairing bonds. A large quantity of miRNAs are involved in intestinal inflammation, mucosal barrier integrity, autophagy, vesicle transportation and other small RNA alterations in IBD circumstance. In this review, the immunomodulatory roles of gut flora and microRNAs are updated in the occurrence and progression of IBD. Meanwhile, the gut flora and microRNA targeted therapeutic strategies as well as other immunomodulatory approaches including TNF-α monoclonal antibodies are also emphasized in the treatment of IBD.

Citing Articles

Contribution of the Gut Microbiome to the Perpetuation of Inflammation in Crohn's Disease: A Systematic Review.

Paidimarri S, Ayuthu S, Chauhan Y, Bittla P, Mirza A, Saad M Cureus. 2024; 16(8):e67672.

PMID: 39314611 PMC: 11419584. DOI: 10.7759/cureus.67672.


The METTL3/miR-196a Axis Predicts Poor Prognosis in Non-small Cell Lung Cancer.

Yang Z, Hao J, Qiu M, Liu R, Mei H, Zhang Q J Cancer. 2024; 15(6):1603-1612.

PMID: 38370374 PMC: 10869973. DOI: 10.7150/jca.92968.

References
1.
Kaplan G, Windsor J . The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020; 18(1):56-66. PMC: 7542092. DOI: 10.1038/s41575-020-00360-x. View

2.
Feuerstein J, Cheifetz A . Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clin Proc. 2017; 92(7):1088-1103. DOI: 10.1016/j.mayocp.2017.04.010. View

3.
Sykora J, Pomahacova R, Kreslova M, Cvalinova D, Stych P, Schwarz J . Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018; 24(25):2741-2763. PMC: 6034144. DOI: 10.3748/wjg.v24.i25.2741. View

4.
Feuerstein J, Moss A, Farraye F . Ulcerative Colitis. Mayo Clin Proc. 2019; 94(7):1357-1373. DOI: 10.1016/j.mayocp.2019.01.018. View

5.
da Silva B, Lyra A, Rocha R, Santana G . Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014; 20(28):9458-67. PMC: 4110577. DOI: 10.3748/wjg.v20.i28.9458. View